NorthStar Medical Radioisotopes in Beloit, Wis. and the Janesville, Wisconsin-planned SHINE Medical Technologies may receive a portion of the $20 million in federal technology funding bill approved by President Donald Trump to produce molybdenum-99 (Mo-99), according to a statement from U.S. Sen. Tammy Baldwin, (D-Wisconsin).
In February, NorthStar received U.S. Food and Drug Administration (FDA) approval for the production process of the key medical isotope—it would be the first to domestically produce the isotope in nearly 30 years.
Baldwin and Sen. Rob Portman, (R-Ohio) worked to include the $20 million technology amendment in the final technology funding bill.
“This appropriations legislation gets our domestic production back on track to ensure health care providers can source this critical medical isotope domestically and reduce our reliance on foreign sources,” Baldwin said in the statement. “I am proud to provide results for our Made in Wisconsin companies that create and innovate to improve public health and save lives."
Matt joined Chicago’s TriMed team in 2018 covering all areas of health imaging after two years reporting on the hospital field. He holds a bachelor’s in English from UIC, and enjoys a good cup of coffee and an interesting documentary.